Patent US5202130A successfully refreshed from Google Patents.
US5202130A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Suppression of eczematous dermatitis by calcium transport inhibition
Assignee: Johns Hopkins University
•
Filing: 1989-08-31
•
Granted: 1993-04-13
•
Expires: 2009-08-31
Abstract
Abstract Treatment of an animal with calcium flux inhibitors results in a decrease in the number of epidermal Langerhans cells and a simultaneous decrease in the ability to respond to contact sensitizing agents. Also, topical application of calcium flux inhibitors will reduce inflammation in patients experiencing delayed-type hypersensitivity reaction or atopic eczema. Thus, calcium flux inhibitors represent a new class of therapeutic agents in the treatment of contact dermatitis and eczema.
Inventors
- 👤 Anhalt Grant
- 👤 Diezel Wolfgang
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 19:36
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/28; A61K33/00; A61K33/24; A61K33/244
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
45 words
A method for the treatment of cutaneous delayed-type hypersensitivity (DTH) in an animal comprising administering to said animal a therapeutically effective amount of a calcium flux inhibiting compound selected from the group consisting of lanthanide ions which are calcium analogs and organic calcium channel blockers.
Claim 2
Independent Claim
45 words
A method for the treatment of cutaneous delayed-type hypersensitivity (DTH) in an animal comprising administering to said animal a therapeutically effective amount of a calcium flux inhibiting compound selected from the group consisting of lanthanide ions which are calcium analogs and organic calcium channel blockers.
Claim 3
Dependent Claim
15 words
The method of claim 1 wherein the calcium flux inhibiting compound is a lanthanide ion.
Claim 4
Dependent Claim
12 words
The method of claim 2 wherein the lanthanide is La +3 .
Claim 5
Dependent Claim
37 words
The method of claim 1, 2, or 3 wherein the calcium flux inhibiting compound is administered prior to exposure of the animal to a contact antigen so as to suppress sensitization of said animal to said antigen.
Claim 6
Dependent Claim
29 words
The method of claim 1, 2, or 3 wherein the calcium flux inhibiting compound is administered to the animal after the animal has been sensitized to a contact antigen.
Claim 7
Dependent Claim
18 words
The method of claim 1, 2 or 3 wherein the calcium flux inhibitor is administered by topical application.
Claim 8
Dependent Claim
23 words
The method of claim 6 wherein the calcium flux inhibitor is applied in a pharmaceutical composition comprising a carrier acceptable for topical application.
Claim 9
Dependent Claim
26 words
The method of claim 7 wherein the composition additionally comprises a penetration enhancing material whereby penetration into the skin by the calcium flux inhibitor is promoted.
Claim 10
Dependent Claim
24 words
The method of claim 7 wherein the calcium flux inhibitor is present in the composition at from about 0.001% to about 30% by weight.
Claim 11
Dependent Claim
24 words
The method of claim 7 wherein the calcium flux inhibitor is present in the composition at from about 0.01% to about 20% by weight.
Claim 12
Dependent Claim
25 words
The method of claim 7 wherein the calcium flux inhibitor is present in the the composition at from about 0.1% to about 10% by weight.
Claim 13
Independent Claim
50 words
A method for the treatment of atopic eczema comprising topically applying a calcium flux inhibitor selected from the group consisting of lanthanide ions which are calcium analogs and organic calcium channel blockers to an animal having atopic eczema in an amount sufficient to reduce the inflammation caused by atopic eczema.
Claim 14
Independent Claim
50 words
A method for the treatment of atopic eczema comprising topically applying a calcium flux inhibitor selected from the group consisting of lanthanide ions which are calcium analogs and organic calcium channel blockers to an animal having atopic eczema in an amount sufficient to reduce the inflammation caused by atopic eczema.
Claim 15
Dependent Claim
14 words
The method of claim 12 wherein the calcium flux inhibitor is a lanthanide ion.
Claim 16
Dependent Claim
13 words
The method of claim 13 wherein the lanthanide ion is La +3 .
Claim 17
Dependent Claim
26 words
The method of claim 12, 13 or 14 wherein the calcium flux inhibitor is applied in a pharmaceutical composition comprising a carrier acceptable for topical application.
Claim 18
Dependent Claim
26 words
The method of claim 15 wherein the composition also comprises a penetration enhancing material whereby penetration into the skin by the calcium flux inhibitor is promoted.
Claim 19
Dependent Claim
24 words
The method of claim 15 wherein the calcium flux inhibitor is present in the composition at from about 0.001% to about 30% by weight.
Claim 20
Dependent Claim
24 words
The method of claim 15 where the calcium flux inhibitor is present in the composition at from about 0.01% to about 20% by weight.
Claim 21
Dependent Claim
24 words
The method of claim 15 wherein the calcium flux inhibitor is present in the composition at from about 0.01% to about 10% by weight.
Claim 22
Dependent Claim
70 words
A pharmaceutical composition for the treatment of cutaneous delayed-type hypersensitivity or for the treatment of atopic eczema comprising a therapeutically effective amount of a calcium flux inhibitor selected from the group consisting of lanthanide ions which are calcium analogs and organic calcium channel blockers, a penetration enhancing material whereby penetration into the skin by the calcium flux inhibitor is promoted, and a carrier which is pharmaceutically acceptable for topical application.
Claim 23
Dependent Claim
70 words
A pharmaceutical composition for the treatment of cutaneous delayed-type hypersensitivity or for the treatment of atopic eczema comprising a therapeutically effective amount of a calcium flux inhibitor selected from the group consisting of lanthanide ions which are calcium analogs and organic calcium channel blockers, a penetration enhancing material whereby penetration into the skin by the calcium flux inhibitor is promoted, and a carrier which is pharmaceutically acceptable for topical application.
Claim 24
Dependent Claim
14 words
The composition of claim 20 wherein the calcium flux inhibitor is a lanthanide ion.
Claim 25
Dependent Claim
13 words
The composition of claim 21 wherein the lanthanide ion is La +3 .
Claim 26
Dependent Claim
16 words
The composition of claim 20 wherein the calcium flux inhibitor is an organic calcium channel blocker.
Claim 27
Dependent Claim
48 words
The composition of claims 20, 21, or 22 wherein the carrier is selected from the group consisting of hydrophilic ointment USP, emulsion ointment base (water in oil) USP, hydrophilic petrolatum USP, hydrous wool fat-lanolin USP, white wax-bleached bees wax USP, glycerin, water/propylene glycol 50%/50%, and pure aqueous solution.
Claim 28
Dependent Claim
24 words
The composition of claims 20, 21, or 22 wherein the calcium flux inhibitor is present at from about 0.001% to about 30% by weight.
Claim 29
Dependent Claim
24 words
The composition of claims 20, 21 or 22 wherein the calcium flux inhibitor is present at from about 0.01% to about 20% by weight.
Claim 30
Dependent Claim
24 words
The composition of claims 20, 21 or 22 wherein the calcium flux inhibitor is present at from about 0.1% to about 10% by weight.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-04-12 | 1996-10-12 | 1997-04-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-04-12 | 2000-10-12 | 2001-04-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-04-12 | 2004-10-12 | 2005-04-13 | $7700.00 | Window Closed / Lapsed |